Stocks
Cullinan Therapeutics, Inc.CGEM
NASDAQHealthcareBiotechnology$14.37
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted therapies for cancer, with a lead program focused on a novel antibody-drug conjugate for solid tumors. Investors track CGEM for its pipeline progress and potential in the oncology space.
52W Range: $6.73-$23.19
Congressional Interest in Cullinan Therapeutics, Inc. (CGEM)
No congressional trades have been disclosed for Cullinan Therapeutics, Inc. (CGEM) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CGEM?
No congressional trades found for this stock.